Renaissance Technologies LLC recently announced the acquisition of new stake in Navidea Biopharmaceuticals Inc. (AMEX:NAVB). The institutional investor has increased its shareholding in the Healthcare company by 264.49% to 0.24 million shares with purchase of 0.17 million shares. This fresh investment now brings its stake to 0.73% valued currently at $62391.0. In addition, Allred Capital Management LLC raised its holdings by 54300.0 to 0.16 million shares.
With over 14.36 million Navidea Biopharmaceuticals Inc. (NAVB) shares trading Tuesday and a closing price of $0.12 on the day, the dollar volume was approximately $1.72 million. The shares have shown a negative half year performance of -53.86% and its price on 05/23/23 gained nearly 7.33%. Currently, there are 32.65M common shares owned by the public and among those 22.27M shares have been available to trade.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for NAVB have a consensus price objective of $8.00. The analysts have set the share’s price value over the next 12 months at a high of $8.00 and a low of $8.00. But an upside of 98.5% will see the stock hit the forecast high price target while median target price for the stock is $8.00.
Insiders at the company have transacted a total of 24 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 24 of these insider trades were purchases, accounting for 119,900 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Navidea Biopharmaceuticals Inc. are Vanguard Extended Market Index Fu, Bridgeway Ultra Small Company Mar, and Fidelity Extended Market Index Fu. Vanguard Extended Market Index Fu owns 0.28 million shares of the company’s stock, all valued at over $72441.0. Fidelity Extended Market Index Fu now owns shares totaling to 0.21% of the shares outstanding.
Shares of Navidea Biopharmaceuticals Inc. (AMEX: NAVB) opened at $0.13, up $0.02 from a prior closing price of $0.11. However, the script later moved the day high at 0.1250, up 7.33%. The company’s stock has a 5-day price change of 2.13% and -56.28% over the past three months. NAVB shares are trading -42.86% year to date (YTD), with the 12-month market performance down to -85.28% lower. It has a 12-month low price of $0.10 and touched a high of $1.05 over the same period. NAVB has an average intraday trading volume of 448.39K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -29.28%, -49.42%, and -56.87% respectively.
Institutional ownership of Navidea Biopharmaceuticals Inc. (AMEX: NAVB) shares accounts for 4.70% of the company’s 32.65M shares outstanding. Mutual fund holders own 26.50%, while other institutional holders and individual stakeholders account for 4.05% and 1.50% respectively.
It has a market capitalization of $4.15M and a beta (3y monthly) value of 1.58. The earnings-per-share (ttm) stands at -$0.50. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.39% over the week and 13.48% over the month.
Analysts forecast that Navidea Biopharmaceuticals Inc. (NAVB) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2024. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Navidea Biopharmaceuticals Inc. (NAVB) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
